The effect of different intensity walking programs on resistin and visfatin levels in pre-menopausal women
Aim: The aim of the study was to examine the effect of two different intensity (walking speeds) walking programs on resistin and visfatin levels in pre-menopausal women. Material and Methods: Thirty-seven pre-menopausal women (30-49 years) were divided into a high-intensity walking group (HIWG; n=12), a moderate-intensity walking group (MIWG; n=14), and a control group (CG; n=11). The exercise groups walked for twelve weeks, five days per week from 30-60min/day. The HIWG and MIWG walked at 70-75% and 50-55% maximum heart rate reserve, respectively. Body weight, percent body fat, body mass index (BMI), waist circumference (WC), maximal oxygen consumption (VO2max), glucose, insulin, resistin, and visfatin were measured; the HOMA-IR (homeostasis model assessment of insulin resistance) index was calculated before and after the study. Results: VO2max improved in both exercise groups (p
Farklı siddetteki yürüyüs programlarının pre-menopozal kadınlarda resistin ve visfatin düzeyleri üzerine etkisi
Amaç: Çalısmanın amacı on iki haftalık, iki farklı siddette (yürüme hızında) yapılan yürüyüs programlarının resistin ve visfatin düzeyleri üzerine etkisini incelemekti. Yöntem ve Gereç: Otuz yedi pre-menopozal kadın (30-49 yas) hızlı tempo yürüyüs grubu (HTYG; n= 12), orta tempo yürüyüs grubu (OTYG; n=14) ve kontrol grubu (KG; n= 11) olarak ayrıldı. Egzersiz grupları 12 hafta, haftada bes gün, günde 30-60 dakika yürüdüler. HTYG ve OTYG maksimum kalp atım sayısı yedeğinin sırasıyla %70-75 ve %50- 55’inde yürüdüler. Antrenman periyodundan önce ve sonra vücut ağırlığı (VA), vücut yağ oranı (VYO), beden kitle indeksi (BKĐ), bel çevresi (BÇ), maksimal oksijen tüketimi (VO2max), glikoz, insülin, resistin ve visfatin düzeyleri ölçüldü; HOMA-IR (insülin direncinin homostatik model değerlendirilmesi) hesaplandı. Bulgular: VO2max her iki egzersiz grubunda (p<.01), HTYG lehine (p<.01) arttı; VA, VYO, BKĐ, BÇ egzersiz gruplarında anlamlı olarak azaldı. Visfatin (p<.05) ve resistin (p<.01) sadece HTYG’de azaldı; gruplar arasında farklılık belirlenmedi. Egzersiz grupları VYO, BÇ ve VO2max bakımından KG’den farklılık gösterdi. HTYG’de BÇ’de meydana gelen azalma OTYG’dekinden daha fazlaydı (p<.01). OTYG’de insülindeki anlamlı artısın (p<.05) dısında, insülin, glikoz, ve HOMA-IR indeksinde grup içi ve gruplar arası farklılık belirlenmedi. Sonuç: Farklı siddette yapılan yürüme programları olumlu değisikliklere neden oldu, ancak, VO2max’daki daha fazla artıslar ve VYO, resistin ve visfatin düzeylerindeki daha fazla azalmalara bağlı olarak, kardiak fitnesi arttırmak, obesiteyi önlemek ve insülin direncini azaltmak için pre-menopozal sağlıklı kadınlara hızlı tempo yürüyüs önerilebilir.
___
1. World Health Organization. Physical status: The use and interpretation of anthropometry. World Health Organ Tech Rep Ser 1995; 854:1-452.2. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993; 119:655-660.
3. Steppan, CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307-312.
4. Kawanami D, Maemura K, Takeda N, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: A new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004; 314:415-419.
5. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: Further evidence of adipokine-endothelial interaction. Circulation 2003; 108:736-740.
6. Yang RZ, Huang Q, Xu A, et al. Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun 2003; 310:927-935.
7. Frankel DS, Vasan RS, D’Agostino RB, et al. Resistin, adiponectin, and risk of heart failure: The Framingham Offspring Study. J Am Coll Cardiol 2009; 53(9):754-762.
8. Pischon T, Bamberger CM, Kratzsch J, et al. Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005; 13:1764-1771.
9. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307:426-430.
10. Berndt J, Klöting N, Kralish S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54:2911-2916.
11. Arner P. Visfatin–a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91:28-30.
12. Klöting N, Klöting I. Visfatin: Gene expression in isolated adipocytes and sequence analysis in obese WOKW rats compared with lean control rats. Biochem Biophys Res Commun 2005; 332(4):1070-1072.
13. Pagano C, Pilon C, Oliveri M, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006; 91:3165-3170.
14. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
15. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group: prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350.
16. Jakicic, JM, Clark, K, Coleman, E, et al. American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2001; 33:2145-2156.
17. NIH Consensus Conference. Physical activity and cardiovascular health. JAMA 1996; 276:241-246.
18. Monzillo LU, Hamdy O, Horton ES, et al. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res 2003; 11(9):1048-1054.
19. Giannopoulou I, Fernhall B, Carhart R, et al. Effects of diet and/or exercise on the adipocytokine and inflammatory cytokine levels of postmenopausal women with type 2 diabetes. Metabolism 2005; 54(7):866-875.
20. Kadoglou NP, Perrea D, Iliadis F, et al. Exercise reduces resistin and inflammatory cytokines in patients with type 2 diabetes. Diabetes Care 2007; 30(3):719-721.
21. Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91:295-299.
22. Haider DG, Pleiner J, Francesconi M, et al. Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes. J Clin Endocrinol Metab 2006; 91:4702-4704.
23. Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007; 56:565-570.
24. Haider DG, Schindler K, Schaller G, et al. Increased plasma visfatin concentrations in morbididly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91:1578-581.
25. Nolan JJ. Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus. Diabetes Obes Metab 2008; 10:593-602.
26. Haus JM, Solomon TPJ, Marchetti CM, et al. Decreased visfatin after exercise training correlates with improved glucose tolerance. Med Sci Sports Exerc 2009; 41(6):1255-1260.
27. Choi KM, Kim JH, Cho GJ, et al. Effect of exercise training on plasma visfatin and eotaxin levels. Eur J Endocrinol 2007; 157:437-442.
28. Berkeley Nutrition Services. Free Dietary Screeners. http://www.nutritionquest.com (accessed on February 15, 2009)
29. Laukkanen R, Oja P, Pasanen M, Vuori I. Validity of a two kilometer walking test for estimating maximal aerobic power in overweight adults. Int J Obes Relat Metab Disord 1992; 16(4):263-268.
30. Oja P, Laukkanen R, Pasanen M, et al. A 2-km walking test for assessing the cardiorespiratory fitness of healthy adults. Int J Sports Med 1991; 12(4):356-362.
31. The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults (American College of Sports Medicine Position Stand). Med Sci Sports Exerc 1998; 30:975-991.
32. Misra A, Vikram NK. Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots. Nutrition 2003; 19:457-466.
33. Seidell JC, Perusse L, Despres JP, Bouchard C. Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors, The Quebec Family Study. Am J Clin Nutr 2001; 74:315-321.
34. Zhu S, Wang Z, Heshka S, et al. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. Am J Clin Nutr 2002; 76:743-749.
35. Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311:158-161.
36. McTiernan A, Sorensen B, Irwin ML, et al. Exercise effect on weight and body fat in men and women. Obesity (Silver Spring) 2007; 15:1496-1512.
37. Vainionpaa A, Korpelainen R, Kaikkonen H, et al. Effect of impact exercise on physical performance and cardiovascular risk factors. Med Sci Sports Exerc 2007; 39:756-763.
38. Bergström I, Lombardo C, Brinck J. Physical training decreases waist circumference in postmenopausal borderline overweight women. Acta Obstet Gynecol Scand 2009; 88(3):308-313.
39. Sternfeld B, Wang H, Quensberry CP, Jr., et al. Physical activity and changes in weight and waist circumference in midlife women: Findings from the study of women’s health across the nation. Am J Epidemiol 2004; 160:912-922.
40. Bouchard C, Despres J-P, Tremblay A. Exercise and obesity. Obes Res 1993; 1:133-147.
41. Hubinger L, Mackinnon LT, Lepre F. Lipoprotein(a) (Lp(a)) levels in middle-aged male runners and sedentary controls. Med Sci Sports Exerc 1995; 27(4):490-496.
42. Park SK, Park JH, Kwon YC, et al. The effect of long-term aerobic exercise on maximal oxygen consumption, left ventricular function and serum lipids in elderly women. J Physiol Anthropol 2003; 22(1):11-17.
43. Blair SN, Kohl HW, Paffenbarger RS, et al. Physical fitness and all-cause mortality: A prospective study of healthy men and women. JAMA 1989; 262:2395-2401.
44. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289:1799-1804.
45. Kelly AS, Steinberg J, Olson TP, Dengel DR. In the absence of weight loss, exercise training does not improve adipokines or oxidative stress in overweight children. Metabolism 2007; 56:1005-1009
46. Frydelund-Larsen L, Akerstrom T, Nielsen S, et al. Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise. Am J Physiol Endocrinol Metab 2007; 292:E24-E31.
47. Brema I, Hatunic M, Finucane F, et al. Plasma visfatin is reduced after aerobic exercise in early onset type diabetes mellitus. Diabetes, Obes Metab 2008; 10(7):600-602.
48. Jürimäe J, Rämson R, Mäestu J, et al. Plasma Visfatin and Ghrelin Response to Prolonged Sculling in Competitive Male Rowers. Med Sci Sports Exerc 2009; 41(1):137-143.
- ISSN: 1016-9113
- Yayın Aralığı: Yılda 4 Sayı
- Başlangıç: 1962
- Yayıncı: Ersin HACIOĞLU
Sayıdaki Diğer Makaleler
Postmortem akciğer doku biyopsisinde vankomisine dirençli enterokok
M IŞIKGÖZ TASBAKAN, B. ARDA, F. BACAKOĞLU, H. PULLUKÇU, A TURHAN, M TOMBULOĞLU, S. ULUSOY
Ö K BAŞOĞLU, B S YÜREKLİ, P TAŞKIRANLAR, Ş TUNÇEL, C. YILMAZ
Molecular evaluation of cytokeratin 20 mRNA expression of transitional cell carcinoma cases
S. YILMAZ, Ç B AVCI, Z O D ŞIĞVA, O. NAZLI, C. GÜNDÜZ
Meningomiyeloselli hastalarda leptin ile vücut kitle indeksi arasındaki iliski
S GÖKAY, Ü. TIRAŞ, E. ŞİMŞEK, U YASITLI, Y. DALLAR
Spinal tüberkülozda (Pott Hastalığı) multimodal analjezi
C. EYİGÖR, A PİRİM, E ÇAĞIRAN, M. UYAR
G BÜYÜKYAZI, H ESEN, F GÖZLÜKAYA, İ ÖZCAN, H TIKIZ, C ULMAN, F TANELİ
Es zamanlı vulva ve kolon kanseri
A ÖZSARAN, C Y SANHAL, C. ÇALIŞKAN, M C TEREK, O. ZEKİOĞLU
Çocukluk ve gençlik dönemindeki özkıyım girisimlerinin değerlendirilmesi
Z YALAKİ, M.A. TAŞAR, N YALÇIN, Y. DALLAR
MDAH- 2774 over kanser kök hücrelerinde kemoterapi sonrası apoptotik etkilerin incelenmesi
S B DEMİRAY, Ş AYLA, F OLTULU, T ÇAVUŞOĞLU, Ö AKARCA, Ö Y DİLSİZ, M. ERGÜVEN, G ÖKTEM, A BİLİR